法匹拉韦治疗拉沙热:开放标签随机对照2期试验
在尼日利亚两家参考医院开展的开放标签随机对照2期试验,评估法匹拉韦对比利巴韦林治疗急性拉沙热的安全性和药代动力学。41例住院成人患者随机分组(利巴韦林21例,法匹拉韦20例),主要终点达标,法匹拉韦暴露可靠且耐受良好,所有参与者存活出院。
要点
- 法匹拉韦在稳态下Cmax为50.9 mg/l,半衰期10.9 h,AUC(0-240h)为9,275 mg/l·h。
- 30例药物相关不良事件两组分布均衡,法匹拉韦组16例(53.5%),无严重或重度事件。
- 利巴韦林组最常见贫血,法匹拉韦组最常见呕吐;所有参与者存活出院。
核心结论
- 法匹拉韦可能是安全且耐受良好的拉沙热替代治疗方案,药代动力学数据支持未来优化方案评估。
研究设计与样本
- 在尼日利亚两家参考医院开展的开放标签随机对照2期临床试验,纳入41例RT-PCR确诊的轻中度拉沙热住院成人患者。
主要发现
- 法匹拉韦一室模型分析显示稳态Cmax为50.9(IQR 42.1–75.1)mg/l,半衰期10.9(IQR 8.2–17.1)h,AUC(0-240h)为9,275(IQR 7,139.4–15,794.8)mg/l·h。
- 30例药物相关治疗中出现的不良事件两组分布均衡,法匹拉韦组16例(53.5%),均未归类为重度或严重。
- 利巴韦林组最常见不良事件为贫血,法匹拉韦组为呕吐;所有参与者存活并成功从隔离病房出院。
关键数值与推荐
- 主要终点为描述经典药代动力学参数(Cmax、Tmax、AUC、半衰期、分布容积)及法匹拉韦对比利巴韦林的安全性和耐受性,主要终点已达标。
临床怎么用
- 法匹拉韦可作为拉沙热住院患者的安全且耐受良好的替代治疗选择,药代动力学数据提示可优化给药方案供后续临床评估。
局限性
- 开放标签设计、样本量较小(41例随机,36例完成10天随访),可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lassa fever (LF) is a viral hemorrhagic fever endemic to West Africa, with high case fatality in hospitalized patients and limited treatment options, including ribavirin. Preclinical evidence suggests high-dose favipiravir is a promising antiviral treatment alternative. We conducted a randomized controlled open-label phase 2 clinical trial at two reference hospitals in Nigeria to evaluate favipiravir in the treatment of LF. Primary endpoints were the description of classic pharmacokinetic parameters (maximum plasma concentration, time to reach maximum plasma concentration, area under the curve (AUC), half-life and volume of distribution) as well as the safety and tolerability of favipiravir compared with ribavirin in the treatment of acute LF. Hospitalized adult patients with mild-to-moderate RT-PCR-confirmed LF were eligible to participate. In total, 41 patients were randomized (ribavirin n = 21; favipiravir n = 20), and 36 completed the 10-day follow-up period. A total of 19 (46.3%) participants were female, and the median age was 37 years. The primary endpoints were met. Pharmacokinetic analysis of favipiravir in a one-compartment model indicated reliable exposure with maximum plasma concentration of 50.9 (IQR 42.1 to 75.1) mg l-1 in steady state, half-life of 10.9 (IQR 8.2 to 17.1) h and AUC (0-240 h) of 9,275 (IQR 7,139.4 to 15,794.8) mg l-1 h-1. The 30 drug-related treatment-emergent adverse events were evenly distributed between the treatment arms; 16 (53.5%) events occurred in the favipiravir group, and none of these were classified as severe or serious. Anemia was the most frequently observed adverse event in the ribavirin arm and vomiting in the favipiravir arm. All study participants survived and were successfully discharged from the isolation ward. This trial indicates favipiravir's potential as a safe and well-tolerated alternative treatment regimen for LF and pharmacokinetic data suggest an optimized favipiravir regimen for future clinical evaluation. Clinicaltrials.gov: NCT04907682 .
引用
- Erameh C, Okwaraeke K, Kleist C, et al. Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial. Nat Med. 2026. PMID: 42141199. doi:10.1038/s41591-026-04402-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。